IP Library › Granted Patent US 12,535,488
Granted Patent B2
US 12,535,488 · App. 17/277,943 · Granted Jan 27, 2026

Screening method for client protein-protecting protein, and physiologically active protein-stabilizing protein and pharmaceutical composition comprising said protein

Inventors: Yukihide Tomari (Tokyo, JP); Shintaro Iwasaki (Tokyo, JP); Kotaro Tsuboyama (Tokyo, JP); Masaaki Oyama (Tokyo, JP); Hiroko Hata (Tokyo, JP); Hiro-oki Iwakawa (Tokyo, JP); Eriko Matsuura (Tokyo, JP)
Assignee: The University of Tokyo
G01N33/6839G01N33/15G16B30/10G01N2333/43573G01N2333/4703
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,535,488
App. No.
17/277,943
Granted
Jan 27, 2026
Kind
B2
Abstract

Provided herein is a novel screening method for a client protein-protecting protein, and a physiologically active protein-stabilizing protein and a pharmaceutical composition using the protein. Also provided herein is a method for screening for a client protein-protecting protein, including the step of evaluating stability of a client protein in the presence of a protein having an intrinsically disordered structure. Also provided herein is an agent for stabilizing a physiologically active protein comprising, as an active ingredient, a protein having any one of amino acid sequences of SEQ ID NOs: 1 to 6; and a pharmaceutical composition including the protein and a physiologically active protein.

Claims (14)

1 . A method for screening for a client protein-protecting protein, comprising a step of selecting one or more candidate proteins having an intrinsically disordered structure from a protein population, optionally of mammalian origin, and a subsequent step of evaluating stability of a client protein in the presence of the one or more candidate proteins having the intrinsically disordered structure, and a step of determining that the candidate protein is a client-protein protecting protein when a degree of stability of the client protein in the presence of the candidate protein is above the degree of stability in the absence of the candidate protein or the degree of stability in the presence of a control protein.

2 . The method according to claim 1 , wherein, in the evaluation step, the stability of the client protein is evaluated based on a degree of protection of the client protein from stress, and wherein the stress is optionally one or more selected from the group consisting of physical stresses and chemical stresses.

3 . The method according to claim 1 , wherein the client protein is a physiologically active protein optionally selected from the group consisting of antibodies, antibody fragments, enzymes, hormones, cytokines and interferons and wherein the physiologically active protein is optionally an active ingredient of a medicine.

4 . The method according to claim 3 , which is a method for identifying a protein useful for stabilization of the physiologically active protein.

5 . The method according to claim 3 , wherein the stability of the physiologically active protein is evaluated in accordance with conditions for a stability test required for approval for manufacture of the medicine.

6 . The method according to claim 1 , wherein the client protein is a non-aggregate protein.

7 . The method according to claim 1 , wherein, in the evaluation step, the stability of the client protein is evaluated using a degree of aggregation of the protein as an index, wherein the aggregation of the protein is optionally measured by one or more selected from the group consisting of a filter trap assay or protein localization in a cell, pulse shape analysis (PulSA), phenotype analysis, detection using a protein aggregation detecting dye (thioflavin T (ThT)), and detection using a protein aggregation detecting reagent (ProteoStat), wherein the client protein is optionally an aggregate protein, and wherein the aggregate protein is optionally a protein causing development and/or progression of a disease.

8 . The method according to claim 7 , which is a method for screening for a protein effective in treatment, prevention or improvement of the disease, optionally a disease which develops and/or progresses upon abnormal aggregation of the protein, wherein the disease which develops and/or progresses upon abnormal aggregation of the protein is optionally a neurodegenerative disease.

9 . The method according to claim 1 , wherein the candidate protein is of mammalian origin and wherein the candidate protein is optionally a protein which remains heat-soluble after a heat treatment.

10 . The method according to claim 1 , wherein the candidate protein is a protein in which a median of IUPred scores of all amino acid residues is greater than 0.5, and wherein the candidate protein is optionally a protein in which more than 50% of amino acid residues relative to the entire sequence have an IUPred score of greater than 0.3.

11 . The method according to claim 1 , wherein, in the selection step, the intrinsically disordered structure of the protein is evaluated by an intrinsically disordered region prediction method, and wherein the intrinsically disordered region prediction method is optionally carried out using a program selected from the group consisting of IUPred, D2P2, GlobPlot, GLOBPLOT2, FoldIndex, IsUnstruct, PONDR VL-XT, DisEMBL, PONDR VL3, PONDR VL3H, RONN, PONDR VSL2B, PONDR VSL2P, Spritz, and SLIDER.

12 . The method according to claim 11 , wherein, in the selection step, the intrinsically disordered structure of the protein is evaluated by IUPred and wherein a protein of interest in which a median of IUPred scores of all amino acid residues is greater than 0.5 in IUPred is optionally selected as the candidate protein.

13 . The method according to claim 11 , wherein, in the selection step, the intrinsically disordered structure of the protein is evaluated by analysis based on heat solubility and wherein a protein which is heat-soluble after a heat treatment is optionally selected as the candidate protein.

14 . The method of claim 1 , wherein the candidate protein is determined to be a client protein protecting protein when the candidate protein protects the client protein from denaturation.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2021
From: TOMARI, YUKIHIDE; IWASAKI, SHINTARO; TSUBOYAMA, KOTARO; OYAMA, MASAAKI; HATA, HIROKO; IWAKAWA, HIRO-OKI; MATSUURA, ERIKO
To: THE UNIVERSITY OF TOKYO
Reel/Frame 056373/0910 →
Continuity (2)
Provisional Application 62734329 · Sep 21, 2018
Related Publication 20210349102A1 · Nov 11, 2021
References Cited (40)
JP 200642731A · 2006 [cited by applicant]
WO WO2015125501A1 · 2015 [cited by examiner]
Breydo, Leonid, Jessica W. Wu, and Vladimir N. Uversky. “α-Synuclein misfolding and Parkinson's disease.” Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease 1822.2 (2012): 261-285. [cited by examiner]
Aprile, Francesco A., Pietro Sormanni, and Michele Vendruscolo. “A rational design strategy for the selective activity enhancement of a molecular chaperone toward a target substrate.” Biochemistry 54.32 (2015): 5103-511… [cited by examiner]
Altschul et al., “Basic Local Alignment Search Tool”, J. Mol. Biol., 1990, vol. 215, p. 403-410. [cited by applicant]
Boothby et al., “Tardigrades Use Intrinsically Disordered Proteins to Survive Desiccation”, Molecular Cell, 2017, vol. 65, p. 975-984. [cited by applicant]
Chang et al., “Hsc70 is required for endocytosis and clathrin function in [cited by applicant]
Dietzl et al., “A genome-wide transgenic RNAi library for conditional gene inactivation in [cited by applicant]
Dosztanyi et al., “IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content”, Bioinformatics, 2005, vol. 21:16, p. 3433-3434. [cited by applicant]
Dosztanyi, et al., “The pairwise energy content estimated from amino acid composition discriminates between folded and intrinsically unstructured proteins” J. Mol. Biol. 347, 827-839 (2005). [cited by applicant]
Elden et al., “Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS”, Nature, 2010, vol. 466:7310, p. 1069-1075. [cited by applicant]
Galea et al., “Large-scale Analysis of Thermo-stable, Mammalian Proteins Provides Insights into the Intrinsically Disordered Proteome”, J Proteome Res., 2009, vol. 8:1, p. 211-226. [cited by applicant]
Guo et al., “Nuclear-Import Receptors Reverse Aberrant Phase Transitions of RNA-Binding Proteins with Prion-like Domains”, Cell, 2018, vol. 173, p. 677-692. [cited by applicant]
Hagedorn et al., “ [cited by applicant]
Iwasaki et al., “Defining funamental steps in the assembly of the Drosophia RNAi enzyme complex”, Nature, 2015, vol. 521, p. 533-549. [cited by applicant]
Jovicic et al., “Modifiers of C9orf72 DPR toxicity implicate nucleocytoplasmic transport impairments in c9FTD/ALS”, Nat Neurosci., 2015, vol. 18:9, p. 1226-1229. [cited by applicant]
Kaken, “Search Research Projects 2016 Fiscal Year Research Status Report”, 2018. [cited by applicant]
Kim et al., “Thermal Behavior of Proteins: Heat-Resistant Proteins and Their Heat-Induced Secondary Structural Changes”, Biochemistry, 2000, vol. 39, p. 14839-14846. [cited by applicant]
Krobitsch et al., “Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins”, PNAS, 2000, vol. 97:4, p. 1589-1594. [cited by applicant]
Kumar et al., “Molecular Chaperone Hsp70 and Its Constitutively Active Form Hsc70 Play an Indispensable Role During Eye Development of Prosophila melanogaster”, Mol Neurobiol, 2017, p. 1-17. [cited by applicant]
Layton et al., “Large-scale, quantitative protein assays on a high-throughput DNA sequencing chip”, Mol Call, 2019, vol. 73:5, p. 1075-1082. [cited by applicant]
Liu et al., “Intrinsically Disordered Proteins as Important Players during Desiccation Stress of Soybean Radicles”, Journal of Proteome Research, 2017, vol. 16, p. 2393-2409. [cited by applicant]
Mori et al., “The C9orf72 GGGGCC Repeat Is Translated into Aggregating Dipeptide-Repeat Proteins in FTLD/ALS”, Sciencexpress, 2013, vol. 330, p. 1-7. [cited by applicant]
Neumann et al., “Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis”, Science, 2006, vol. 314, p. 130-133. [cited by applicant]
Nonaka et al., “Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43”, Human Molecular Genetics, 2009, vol. 18:18, p. 3353-3364. [cited by applicant]
Panganiban et al., “Random heteropolymers preserve protein function in foreign environments”, Science, 2018, vol. 359, p. 1239-1243. [cited by applicant]
Pearson, “Rapid and Sensitive Sequence Comparison with FASTP and FASTA”, Methods in Enzymology, 1990, vol. 183, p. 63-98. [cited by applicant]
Tsuboyama et al., “Conformational Activation of Argonaute by Distinct yet Coordinated Actions of the Hsp70 and Hsp90 Chaperone Systems”, Molecular Cell, 2018, vol. 70, p. 722-729. [cited by applicant]
Tsuboyama et al., “Functional analysis of heat-resistant proteins”, Conference program of the Japanese Biochemical Society, Sep. 3, 2018. [cited by applicant]
Tsvetkov et al., “Thermo-resistant intrinsically disordered proteins are efficient 20S proteasome substrates”, Mol. BioSyst, 2012, vol. 8, p. 368-373. [cited by applicant]
Uhlen et al., “Tissue-based map of the human proteome”, Science, 2015, vol. 347:6220, p. 1-12. [cited by applicant]
Warrick et al., “Expanded Polyglutamine Protein Forms Nuclear Inclusions and Causes Neural Degeneration in [cited by applicant]
Waterman, “Computer Analysis of Nucleic Acid Sequences”, Methods in Enzymology, 1988, vol. 164, p. 756-793. [cited by applicant]
Wilbur et al., “Rapid similarity searches of nucleic acid and protein data banks”, Proc. Natl. Acad. Sci. USA, 1983, vol. 80, p. 726-730. [cited by applicant]
Zhang et al., “Exploring intrinsically disordered proteins in Chlamydomonas reinhardtii”, Scientific Reports, 2018, vol. 8:6805, p. 1-11. [cited by applicant]
Ahn et al., “Chaperone-like activities of alpha-synuclein: alpha-synuclein assists enzyme activities of esterases”, Biochemical and Biophysical Research Communications, 2006, pp. 1142-1149, vol. 346. [cited by applicant]
Chakrabortee et al., “Catalytic and chaperone-like functions in an intristically disordered protein associated with desiccation tolerance”, PNAS, 2010, pp. 16084-16089, vol. 107, No. 37. [cited by applicant]
Liu et al., “Both plant and animal LEA proteins act as kinetic stabilisers of polyglutamine-dependent protein aggregation”, FEBS Letters, 2011, pp. 630-634, vol. 585. [cited by applicant]
Popova et al., “The intristically disordered protein LEA7 from [cited by applicant]
Yuen et al., “Preferential adsorption to air-water interfaces: a novel cryoprotective mechanism for LEA proteins”, Biochemical Journal, 2019, pp. 1121-1135, vol. 476. [cited by applicant]